Biogazelle strengthens its board of directors
on February 6, 2015
On October 6, 2014, Biogazelle announced the closure of an investment round with QBIC Arkiv Fund, Foundation Majoie and SOFI to finance its growth (press release available on http://bgzlle.com/2bCDGtm). Today, Biogazelle announces that it has strengthened its board with two directors representing the new investors and also announces its intention to propose the nomination of Nick McCooke and Jim Van heusden as non-executive directors to the next shareholder meeting. Biogazelle’s board also has the intention to separate the roles of chairman and CEO. The board intends to elect Mr McCooke as chairman to succeed Jan Hellemans who will remain chief executive officer. The new members will join the current board members (Jan Hellemans (CEO), Jo Vandesompele (CSO), Bert D’Huyvetter (CFO) and Marc Schijvaerts) who retain their appointment.
Nick McCooke, independent chairman
Nick is an experienced and successful bio-entrepreneur, well-known for building and leading the Solexa team that pioneered Next Generation Sequencing (NGS), technology that became the basis of Illumina’s current market-leading product line. Apart from his base in the UK, Nick has lived and worked in the USA, Japan and Belgium. He acted as CEO of Pronota, interim COO of Cambridge Epigenetix, part-time CEO of Oxford Cancer Biomarkers and CEO of Solexa. Nick is currently CBO of DNA Electronics, a non-executive director of Bioventix PLC and a trustee of the Association of Medical Research Charities.
Bernard Majoie, representing Foundation Majoie
Bernard Majoie is founder of the research & development laboratory of the Fournier Group. He acted as CSO, CEO and finally Chairman of the board at Fournier Pharmaceutical Group. When retiring he played a Business Angel activity helping start-ups in Belgium and France. He is currently chairman and founder of the Fournier-Majoie Foundation dedicated to support innovative and entrepreneurial teams in biomolecular applications leading to improvements of cancer treatments.
Els Hubloux, representing QBIC Arkiv Fund
Els is an Investment Partner at QBIC Venture Partners. She has over 18 years of experience in the life sciences sector, of which 12 years as a venture capital professional. She has also acted as CFO of a diagnostics start-up and has been a director of a number of companies, including Algonomics, Nexstim, Sequana Medical, Sphere Medical and TcLand Expression.
Jim Van heusden, independent board member appointed by SOFI
Jim Van heusden is Managing Director of bioskills, providing fundraising services and strategic advice to biotech companies and life science funds. He has over 20 years of experience in the life sciences sector, of which 12 years as a venture capital investor in biotech companies at Gimv.
Jim has an excellent and proven track record in building successful companies. He has served on a number of boards including Ablynx, Actogenix, Multiplicom, Pronota, Prosensa, and currently FlandersBio and Ovizio Imaging Systems.
Biogazelle is a Ghent University spin-off founded in 2007 by prof. Jo Vandesompele and dr. Jan Hellemans. Biogazelle offers expert laboratory services (some of which under ISO 17025 accreditation) in the area of gene expression analysis. To this purpose, several state-of-the-art laboratory methods such as RNA sequencing and digital PCR are being used, complemented with custom developed unique software tools, including qbase+ for RT-qPCR data-analysis.
Being at the forefront of the genomics revolution, Biogazelle is convinced that unraveling the coding and non-coding regions of the genome will lead to RNA targeted biomarkers and treatments for better healthcare. Its mission is to understand the transcriptome for next generation diagnostics and therapeutics through excellence in science and technology.
Biogazelle continues to build on its core values of collaboration, courage, passion and open communication.